Board Changes at Novogen Limited Announced

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 23, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William D. Rueckert to its Board of Directors.

The advantage for Novogen of Mr. Rueckert becoming a director is that he is already familiar with the group, having been a director for two years on the boards of subsidiaries, Glycotex and Marshall Edwards, and brings considerable U.S. based commercial experience.

Mr. Rueckert is the Managing Member of Oyster Management Group, LLC and is a director of Glycotex, Inc., an 83 percent owned unlisted subsidiary of Novogen Limited. Mr. Rueckert was formerly a director of Emergency Filtration Products, Inc., a public manufacturer and marketer of respiratory filtration devices, and President and Director of Eastern Capital Development, LLC since 1999. He also served as President and Director of Rosow & Company, a private investment firm based in Connecticut since 1990, Treasurer of Moore & Munger, Inc., a company with interests in the petroleum and resort development industries from 1988 to 1990, and was President of United States Oil Company, a publicly traded oil exploration business from 1981 to 1988. Among his many civic association affiliations, Mr. Rueckert is Director and President of the Cleveland H. Dodge Foundation, a private philanthropic organization in New York City and Chairman of the Board of the Trustees of Teachers College at Columbia University.

Mr. Rueckert has resigned as a director of Marshall Edwards Inc., the 72 percent U.S. subsidiary of Novogen Limited.

Welcoming Mr. Rueckert to the Novogen board, Chairman Philip Johnston said his particular expertise and experience would bring additional strong commercial acumen to the Board and in particular his knowledge of all facets of the U.S. capital markets. His two years on the boards of Marshall Edwards and Glycotex have further equipped Mr. Rueckert with a detailed understanding of the operations of the Novogen Group.

Novogen Limited also announces that Mr. Peter Simpson will retire as a director prior to June 30, 2009.

At Novogen's AGM last year, Mr. Simpson, having been a director for 15 years, indicated his intention to resign this year after a suitable replacement was found.

About Novogen Limited and Marshall Edwards, Inc.

Novogen Limited is an Australian biotechnology company based in Sydney, Australia, that is developing a range of oncology therapeutics from its proprietary flavonoid synthetic chemistry technology platform. Marshall Edwards, Inc. (NASDAQ: MSHL) is a majority owned US subsidiary of Novogen which has licensed rights from Novogen to undertake clinical trials to bring three of its oncology drugs -- phenoxodiol, triphendiol (NV-196) and NV-143 -- to market globally. More information on phenoxodiol, triphendiol, NV-128 and on the Novogen group of companies can be found at www.novogen.com and at www.marshalledwardsinc.com. More information about Marshall Edwards' Phase III clinical trial OVATURE, in which phenoxodiol is being studied in conjunction with weekly carboplatin for its efficacy in treating advanced ovarian cancer can be found by visiting www.ovaturetrial.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Contact Information: FOR FURTHER INFORMATION: MR CHRISTOPHER NAUGHTON MANAGING DIRECTOR NOVOGEN LIMITED TEL +61 (02) 9878 0088 http://www.novogen.com ISSUED BY: WHITECOAT Strategies CONTACT: David Sheon 202 547-2880